Reliability of the Samsung Galaxy for the Detection of Moderate to Severe Obstructive Sleep Apnea
Launched by STANFORD UNIVERSITY · Sep 17, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well the Samsung Galaxy smartphone can detect moderate to severe obstructive sleep apnea (OSA), a condition where breathing repeatedly stops and starts during sleep. The researchers want to see if this device can be a reliable tool for identifying people who have this sleep disorder. The trial is currently recruiting participants aged 22 and older who have a high likelihood of having OSA based on certain screening questionnaires or who have already been diagnosed with the condition.
To participate, individuals should be generally healthy and not have severe medical or psychiatric conditions that could interfere with the study. Participants will need to use a Samsung Galaxy device for sleep tracking and spend two nights in a sleep lab for monitoring. This study aims to improve how we diagnose sleep apnea, which can lead to better treatment options for those affected. If you or a loved one is interested in joining, it's important to review the eligibility criteria carefully and discuss any questions with your healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 22 years of age or older
- • High pre-test likelihood of moderate to severe obstructive sleep apnea (OSA) based on screening questionnaires (STOP-Bang and Epworth Sleepiness Scale); or prior diagnosis of moderate-severe OSA.
- • Able to provide informed consent confirmation
- Exclusion Criteria:
- • Severe and/or other acute medical illnesses as determined by the Investigator, in particular: Cardiac conditions such as Congestive Heart Failure (CHF), atrial fibrillation, Hx of Movement disorders: Parkinson's, Tremor, Lung conditions: Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, emphysema, pulmonary fibrosis, acute episode of flu, allergies, asthma.
- • Active comorbid sleep disorders, such as severe insomnia, restless legs syndrome, Periodic Leg Movement During Sleep (PLMS), narcolepsy, idiopathic hypersomnia
- • Severe and/or unstable psychiatric disorders such as mood, anxiety, or psychotic disorders
- • Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk
- • Inability to use a Samsung Galaxy device for sleep tracking
- • Inability to have two nights in the Stanford sleep lab.
- • Participants who are pregnant
- • Tattoos or scars covering the forearm area of both hands
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Trial Officials
Robson Capasso, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported